Pathogen group cutting -edge forum No. 11: Intelligent decision -making and clinical precision treat

Lecture information

Lecture theme: Intelligent decision -making and clinical precision treatment of lung cancer diagnosis and treatment series of innovative technologies

Date: June 14, 2022 (Tuesday) 20: 00-21: 30

way of participation:

1. Tencent Conference (Limited 300 people, first come first first!)

Tencent Conference Number: 239-808-504

Meeting link:

https://meeting.tencent.com/dm/qkwxfdzuqh

2. "Human Pathum Group Project" live video number live broadcast

Scan the code to follow the video number appointment and watch the live broadcast

(WeChat video number live broadcast)

3. "Precision Medicine Society" live broadcast live broadcast

Introduction to the guest lecturer:

He Jianxing

Professor He Jianxing, Director of the National Respiratory Medicine Center, Dean of the Guangzhou Institute of Respiratory Health, Professor of Chemical Surgery, Boader, Transplantation, Cancer Academic Leader of the First Affiliated Hospital of Guangzhou Medical University, Fellow Vice President of the Guangdong Medical Association, president of the Guangdong Provincial Frees Diseases Society, Vice President of the Guangdong Provincial Society of Precision Medicine, honorary chairman of the lung cancer branch, and members of the Chinese Human Pathum Group Research Cooperation Group (HPCC).

He is engaged in medical education and research and transformation in the field of lung cancer and transplantation, innovated and developed precision minimally invasive surgery of thoracic surgery, and created new technologies for transplantation technologies such asotherapy for alien cardiopulmonary combined transplantation; lung cancer non -invasive early diagnosis technology improved the premature early diagnosis rate.

Published 354 SCI papers in NEJM and others with first/communication authors; 8 editor -in -chief of English monographs; 16 national invention patents; 1 international invention patent. 1 Studies are written into the WHO new crown prevention guidelines, 1 studies are included in the U.S. Clinical Tumor Guide (NCCN), and the prognostic model of 1 lung cancer was recommended by the National Cancer Institute Knight Center. Won the second prize of National Science and Technology Progress in 2018 (ranked first), and the first prize of National Science and Technology Progress (Innovation Team Award) in 2020.

Report Abstract

Because the lungs are connected at the time of the outside world, lung cancer is the malignant tumor of the incidence and mortality, and the incidence of lung nodules is as high as 48%. The team has developed a precise diagnosis of imaging artificial intelligence combined with CTDNA methylation. The robot auxiliary positioning biopsy technology, the first self -breathing Tubeless technology combined with multimodal brain function detection to achieve precision anesthesia and brain function in the operation. The accurate resection of the naked -eye 3D single -hole without tubular unilateral holes has enabled the treatment of early lung cancer to achieve daytime surgery; applied to the rapid removal biopsy and genetic analysis of the whole lesion, eliminating the mother lesion and its heterogeneity.

Based on the genetic analysis and clinical table type based on the resection full specimen, the postoperative treatment decision -making risk model has been established to achieve accurate postoperative intervention. It avoids invalid treatment, effectively improves the long -term survival and quality of life of patients.

Moderator introduction:

Chen Haiquan

Professor Chen Haiquan, Director of the Institute of chest tumor research at Fudan University, director of thoracic surgery at the Department of Deep Surgery, Affiliated to Fudan University, and Chief Expert of Chief of chest oncology. Member of the Member Development Commission of the American Extraordinary Sciences (AATS), member of the Education Commission, a member of the Standard Committee of the Clinical Practice of the Department of Thoracic Surgery, and a former member of the International Director of the American Chemical Surgery Association (STS) and the two members of the International Relations Department. Vice President of the Chinese Medical Association's Chemical Surgery Branch, the chairman of the Shanghai Medical Association's chest surgery branch, and chairman of the Shanghai Anti -Cancer Association's chest tumor committee. Brigham and Women’s Hospital 20-21 Gerald and Elaine Schuster Distinguished Lecturer.J THORAC CARDIOV SUR编委、J CANCER RES CLIN副主编、JTO Clinical and Research Reports编委、Clinical Surgical Oncology编委。

Research direction: early diagnosis of breast cancer, esophageal cancer and other chest tumors and multi -disciplinary comprehensive treatment based on minimally invasive surgery.

organizer:

Shanghai International Human Pathum Group Research Institute

Phenomics Press Group College Journal

Fudan University Human Pathum Group Research Institute

Chinese Biological Physics Society Press Formation Branch

- END -